What's new?

Added 4 days ago Drug news

Completion of interim statistical assessment and small increase in target enrollment for KALM-2 phase III trial of Korsuva injection in hemodialysis patients with pruritus.- Cara Therapeutics

Cara Therapeutics, Inc. announced the completion of an interim statistical assessment of its pivotal KALM-2 Phase III global clinical trial...

Added 6 hours ago Drug news

CHMP recommends Baqsimi, the first treatment for severe hypoglycaemia administered without an injection to patients with diabetes aged four years and older.- Eli Lilly

EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation in the European Union for Baqsimi (glucagon), from Eli...

Added 6 hours ago Drug news

Herzuma and Truxima biosimilars to be distributed in Australia by Celltrion and to hospitals by Juno Pharmaceuticals.

Celltrion Healthcare (Celltrion) has entered into a partnership with Juno Pharmaceuticals (Juno) ( not to be confused with Juno Therapeutics)...

Added 6 hours ago Drug news

Submission to EMA for Nuzyra in ABSSSI and CABP withdrawn.- Paratek Pharma

Paratek Pharmaceuticals announced that the company has withdrawn its submission to the European Medicines Agency (EMA) of the Marketing Authorization...

Added 6 hours ago Drug news

CHMP recommends approval of Keytruda in head and neck squamous cell carcinoma.- Merck Inc.

Merck announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a...